NCT04301778 2026-03-13
Durvalumab and SNDX-6532 Following Chemo or Radio-Embolization for Patients With Intrahepatic Cholangiocarcinoma
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 2 Completed
Clinical Trials
24 trialsNCT06728410 2026-03-09
A Phase II Study of Pemigatinib Plus Durvalumab in Previously Treated Advanced Intrahepatic Cholangiocarcinoma Patients With FGFR-2 Fusion or Rearrangement
Hoosier Cancer Research Network
Phase 2 Recruiting
NCT06859684 2026-03-09
HAIC-quad
West China Hospital
Phase 2 Recruiting
NCT03942328 2026-02-24
Modified Immune Cells (Autologous Dendritic Cells) and a Vaccine (Prevnar) Combined With Immune Checkpoint Inhibition After High-Dose External Beam Radiation Therapy in Treating Patients With Unresectable Liver Cancer
Mayo Clinic
Phase 1/2 Recruiting
NCT06282575 2026-02-24
Efficacy and Safety of Zanidatamab With Standard-of-care Therapy Against Standard-of-care Therapy for Advanced HER2-positive Biliary Tract Cancer
Jazz Pharmaceuticals
Phase 3 Recruiting
NCT06546969 2025-12-10
Chemoimmunotherapy Combined With Hyperthermia and Spatially-Fractionated Radiotherapy in Advanced Biliary Tract Cancer
University of Maryland, Baltimore
Phase 1 Recruiting
NCT07269158 2025-12-08
A Phase IIb Randomized Clinical Trial of Immune Checkpoint Inhibitor-based Maintenance Therapy in Patients With Advanced Biliary Tract Cancer
Yonsei University
Phase 1/2 Not yet recruiting
NCT03257761 2025-12-05
Guadecitabine and Durvalumab in Treating Patients With Advanced Liver, Pancreatic, Bile Duct, or Gallbladder Cancer
University of Southern California
Phase 1 Active not recruiting
NCT04238637 2025-12-05
Immunotherapy Combined With Y-90 SIRT Therapy in Advanced Stage Intrahepatic Biliary Tract Cancer (BTC)
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
Phase 2 Active not recruiting
NCT06440993 2025-12-01
Durvalumab + Intraductal Radiofrequency Ablation (ID-RFA) in Extrahepatic Cholangiocarcinoma
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
Phase 2 Recruiting
NCT06058663 2025-10-20
Radioembolization With Tremelimumab and Durvalumab for Locally Advanced Unresectable or Oligo-Metastatic Intrahepatic Cholangiocarcinoma
Mayo Clinic
Phase 1 Recruiting
NCT06441747 2025-07-29
Phase II Study of the Combination of Durvalumab (MEDI4736) (PDL1 Inhibitor) and Olaparib (PARP Inhibitor) in Advanced Cholangiocarcinoma After Initial Chemotherapy and Durvalumab (BIL-PPP)
Australasian Gastro-Intestinal Trials Group
Phase 2 Recruiting
NCT04521686 2025-06-27
Study of LY3410738 Administered to Patients With Advanced Solid Tumors With IDH1 or IDH2 Mutations
Eli Lilly and Company
Phase 1 Active not recruiting
NCT05451043 2025-06-26
Durvalumab and Tremelimumab in Combination With Propranolol and Chemotherapy for Treatment of Advanced Hepatopancreabiliary Tumors (BLOCKED)
AHS Cancer Control Alberta
Phase 2 Recruiting
NCT05712356 2025-06-06
BOLSTER
Lisata Therapeutics, Inc.
Phase 2 Active not recruiting
NCT05239169 2025-05-01
Immunotherapy With Durva and Treme With or Without Capecitabine in Adjuvant Treatment for Biliary Tract Cancer
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
Phase 2 Completed
NCT05655949 2025-03-10
Y-90 With Durvalumab/Gem/Cis in Intrahepatic Cholangio
Beth Israel Deaconess Medical Center
Phase 2 Recruiting
NCT06341764 2024-11-07
Neo-adjuvant Chemo and Immunotherapy in the Pre-operAtive Treatment of Locally Advanced CholangIOcarciNoma
National Cancer Institute, Naples
Phase 2 Recruiting
NCT04989218 2024-11-05
ICC
University of Alabama at Birmingham
Phase 1/2 Terminated
NCT06530823 2024-07-31
Pemigatinib Combined With Durvalumab for Previously Treated Biliary Tract Carcinoma
Eastern Hepatobiliary Surgery Hospital
Phase 2 Not yet recruiting
NCT03991832 2024-07-18
SOLID
University Health Network, Toronto
Phase 2 Recruiting
NCT06375915 2024-05-24
PM-CARE
IRCCS San Raffaele
Phase 2 Recruiting
NCT03473574 2023-06-15
IMMUCHEC
AIO-Studien-gGmbH
Phase 2 Completed
NCT05672537 2023-01-05
Durvalumab Combined With GemCis Neoadjuvant Therapy of Resectable Intrahepatic Cholangiocarcinoma With High Recurrence Risk
Tianjin Medical University Cancer Institute and Hospital
Phase 2 Unknown